The University of Tokyo

Tokyo Medical and Dental University

Nanocarrier Co., Ltd.

Kawasaki Institute of Industrial Promotion

Mitsuru Naito

Kazunori Kataoka

Takehiko Ishii

Akira Matsumoto

Kanjiro Miyata

Yasuki Kato

Hiroyuki Chaya

Naoto Yoshinaga

Shigehito Osawa

Taisuke Endo

Beob Soo Kim

A drug-polymer conjugate having thermoresponsiveness includes at least one drug conjugated to at least one end portion of at least one thermoresponsive polymer segment having a lower critical solution temperature. The drug-polymer conjugate is capable of forming a micellular aggregate in an aqueous medium at temperatures equal to or above the lower critical solution temperature. The drug-polymer conjugate or the micellular aggregate thereof may be administered to and absorbed in the lungs.

Temperature-responsive drug/polymer compound and application of compound to drug delivery

A pharmaceutical composition includes polymer units &#x3b1; and &#x3b2;, each having a hydrophilic polymer chain bound to a cationic polymer chain, and a drug. The polymer units &#x3b1; and &#x3b2; are radially arranged such that the cationic polymer chains are directed inward and the hydrophilic polymer chains are directed outward, thereby forming a micelle with the drug encapsulated in the micelle. The cationic polymer chain of the polymer unit &#x3b1; has a phenylboronic acid group in a side chain, and the cationic polymer chain of the polymer unit &#x3b2; has a phenylboronic acid binding site in a side chain. The phenylboronic acid group and the phenylboronic acid binding site form a cross-linked structure that can dissociate in an acidic environment and/or in the presence of a substance capable of competitive binding.

Pharmaceutical composition

A block copolymer includes a polyamino acid chain segment and a hydrophilic polymer chain segment. The polyamino acid chain segment includes at least one amino acid residue having a side chain that contains a cationic group and at least one amino acid residue having a side chain that contains a substituted phenylboronic acid group. In the substituted phenylboronic acid group, at least one hydrogen of the phenyl ring is substituted so that the phenylboronic acid group has a pKa of less than 8. Such a block copolymer serves as a carrier that simultaneously imparts stability to a biotechnology-based drug in blood and provides suitable drug-releasing properties of the drug at an affected area.

Block copolymer having phenylboronic acid group introduced therein, and use thereof

Growing community of inventors

Tokyo, Japan

Mitsuru Naito